EVANS GARY C

UAMY Chairman/CEO Gary Evans buys 100,000 shares ($613.2K) at $6.13; stock up 36.3% in 30d, but his prior UAMY purchase showed -10.2% 90d return

Gary Evans, Chairman & CEO of United States Antimony Corp, purchased 100,000 shares (100.0K shares) at $6.13 on 2025-09-26, bringing his total holdings to 2,378,818 shares (2.38M shares) and increasing his stake by 4.4%. The stock has gained 36.3% over the past 30 days and 191.1% over 90 days, though it remains 15.1% below its 52-week high of $7.30. However, Evans's track record on this specific ticker is cautionary: his prior buy at UAMY on 2024-12-10 showed a 90-day return of -10.2%, and across all his open-market purchases, his 90-day win rate stands at 0.00%. The company reported strong annual revenue growth of +71.8% and a recent quarterly revenue of $10,525,123.00 ($10.5M), but it remains unprofitable, with full-year net income in negative territory. This purchase may reflect conviction in the company's turnaround trajectory, yet the recent momentum in the stock price and the executive's lack of successful 90-day timing outcomes on prior buys warrant close monitoring of whether this price appreciation proves sustainable.

UAMY Chairman & CEO Evans purchases 200,000 shares ($289.4K) at $1.45; holdings increase 15.1% despite company losses

Gary C. Evans, Chairman & CEO of United States Antimony Corp, executed a $289,400 purchase of 200,000 shares at $1.45 per share, increasing his holdings by 15.1% to 1,528,818 shares post-transaction. This substantial equity stake expansion occurs in a context of operational headwinds: the company posted a net loss of $-727,509 over its latest quarter and negative full-year net income, with annual revenue contracting 21.3% year-over-year. The timing is notable given recent price recovery—the stock has rallied 119.2% over the past 30 days and 130.8% over 90 days from severely depressed levels (52-week low of $0.21)—suggesting the CEO's accumulation decision was made after significant appreciation from trough. The purchase price of $1.45 sits at a 3.3% discount to current market price of $1.50 but remains 23.7% below the 52-week high of $1.90, leaving material gap between execution and prior peak valuations.